Home
    • Plans Blog Contact
    MDxHealth SA ADR logo

    MDxHealth SA ADR

    MDXH
    Last price US$0.807
    Market cap US$24.5m
    12M price change -71.59%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    IQVIA Holdings IncIQV Industry peer Agilent Technologies IncA Industry peer Thermo Fisher Scientific IncTMO Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    MDxHealth SA ADR Overview

    Industry: Diagnostics & Research

    Sector: Healthcare

    MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium. MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians wi Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for MDxHealth SA ADR into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 13, 2026

    Quarterly result summary

    Stored reported-result values did not pass automated reconciliation.

    What changed

    • Open the SEC source filing while these values are reprocessed.

    Source review

    Mavefund has withheld unreconciled figures from the public page.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing REPORT OF FOREIGN PRIVATE ISSUER Aug 13, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jul 24, 2026 Earnings release PRESS RELEASE, DATED JULY 24, 2026 Jul 24, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jul 02, 2026 Earnings release PRESS RELEASE, DATED JULY 2, 2026 Jul 02, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER May 13, 2026 Earnings release PRESS RELEASE, DATED MAY 13, 2026 May 13, 2026 SEC filing ANNUAL REPORT Apr 03, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Feb 26, 2026 Earnings release PRESS RELEASE, DATED FEBRUARY 26, 2026 Feb 26, 2026 SEC filing REPORT OF FOREIGN PRIVATE ISSUER Jan 12, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    MDxHealth SA ADR boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Return on Equity

    Score 1.96/5
    MDxHealth SA ADR exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    MDxHealth SA... MDXH US$24.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 2.21/5
    MDxHealth SA ADR olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    MDxHealth SA... MDXH US$24.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Leverage

    Score 1.04/5
    MDxHealth SA ADR registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    MDxHealth SA... MDXH US$24.5m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    MDxHealth SA ADR logo

    MDxHealth SA ADR

    US$0.807

    US$24.5m

    75.01%

    -71.59%